Rezolute マネジメント

マネジメント基準チェック /34

Rezoluteの CEO はNevan Elamで、 Jan2013年に任命され、の在任期間は 11.83年です。の年間総報酬は$ 1.19Mで、 46.1%給与と53.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.014%を直接所有しており、その価値は$ 41.36K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と4.2年です。

主要情報

Nevan Elam

最高経営責任者

US$1.2m

報酬総額

CEO給与比率	46.1%
CEO在任期間	11.8yrs
CEOの所有権	0.01%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

CEO報酬分析

Rezolute の収益と比較して、Nevan Elam の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$69m
Jun 30 2024	US$1m	US$550k	-US$68m
Mar 31 2024	n/a	n/a	-US$58m
Dec 31 2023	n/a	n/a	-US$57m
Sep 30 2023	n/a	n/a	-US$56m
Jun 30 2023	US$974k	US$534k	-US$52m
Mar 31 2023	n/a	n/a	-US$48m
Dec 31 2022	n/a	n/a	-US$44m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	US$8m	US$515k	-US$41m
Mar 31 2022	n/a	n/a	-US$38m
Dec 31 2021	n/a	n/a	-US$31m
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	US$5m	US$496k	-US$21m
Mar 31 2021	n/a	n/a	-US$18m
Dec 31 2020	n/a	n/a	-US$19m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	US$4m	US$490k	-US$20m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	n/a	n/a	-US$37m
Sep 30 2019	n/a	n/a	-US$34m
Jun 30 2019	US$732k	US$453k	-US$33m
Mar 31 2019	n/a	n/a	-US$42m
Dec 31 2018	n/a	n/a	-US$25m
Sep 30 2018	n/a	n/a	-US$27m
Jun 30 2018	US$468k	US$450k	-US$30m

報酬と市場: Nevanの総報酬 ($USD 1.19M ) は、 US市場 ($USD 1.46M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Nevanの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Nevan Elam (57 yo)

11.8yrs

在職期間

US$1,192,700

報酬

Mr. Nevan Charles Elam, J.D., is a Founder of Rezolute, Inc. and serves as its Chief Executive Officer and Director at since January 31, 2013. Mr. Elam serves as Acting Chairman of the Board at Rezolute, I...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Nevan Elam	Founder	11.8yrs	US$1.19m	0.014% $ 41.4k
Daron Evans	Chief Financial Officer	less than a year	US$384.07k	0.36% $ 1.1m
Brian Roberts	Chief Medical Officer	4.8yrs	US$817.96k	0.12% $ 363.6k
Davelyn Hood	Director and Head of Scientific & Patient Affairs	3.5yrs	データなし	データなし
Michael Deperro	Senior VP & Head of Corporate Development	1.8yrs	データなし	データなし
Michael Covarrubias	Senior VP & Head of Program & Portfolio Management	3.7yrs	データなし	データなし
Chris Milks	VP & Head of Finance	no data	データなし	データなし
Raj Agrawal	VP & Head of Ophthalmological Clinical Development	no data	データなし	データなし
Robyn Sweinhart	VP & Head of Quality	no data	データなし	データなし
Erin O'Boyle	Senior VP & Head of Clinical Operations	no data	データなし	データなし
Susan Stewart	Chief Regulatory Officer	2.1yrs	データなし	データなし
Gopal Saha	Senior Vice President of Global Clinical Development	less than a year	データなし	データなし

2.8yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: RZLTの経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Nevan Elam	Founder	11.8yrs	US$1.19m	0.014% $ 41.4k
Jerrold Olefsky	Member of the Scientific Advisory Board	10.6yrs	データなし	データなし
Gilbert Labrucherie	Independent Director	5yrs	US$93.44k	0.10% $ 299.3k
Philippe Fauchet	Independent Director	4.2yrs	US$90.44k	0% $ 0
Young-Jin Kim	Director	5.8yrs	US$45.00k	0.21% $ 610.7k
Scott Morenstein	Board Observer	no data	データなし	データなし
Quan Dong Nguyen	Member of the Scientific Advisory Board	3.5yrs	データなし	データなし
Nerissa Kreher	Independent Director	3.7yrs	US$86.44k	0% $ 0
Robert B. Bhisitkul	Member of the Scientific Advisory Board	no data	データなし	データなし
Wladimir Hogenhuis	Independent Director	3.7yrs	US$93.44k	0.075% $ 220.9k
Adrian Vella	Member of the Scientific Advisory Board	3.2yrs	データなし	データなし
Alvin Schmaier	Member of the Scientific Advisory Board	no data	データなし	データなし

4.2yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: RZLTの取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

Rezolute マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Insufficient new directors

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Chief Financial Officer recently bought US$67k worth of stock

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Recent updates

Price target increased by 7.5% to US$12.78

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Insufficient new directors

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98

Rezolute, Inc. Announces Phase 2B Study of RZ358 Continues to Enroll Congenital Hyperinsulinism (HI) Patients Worldwide

Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

New 90-day low: US$12.94

Rezolute, Inc. Announces Resignation of Jung-Hee Lim as a Member of the Board of Directors, Audit Committee and Compensation Committee

Price target raised to US$31.50

Rezolute, Inc. Announces CFO Changes

Rezolute, Inc. announced that it expects to receive $40.92 million in funding from BVF Partners LP, Citadel Advisors LLC, and other investors

Rezolute, Inc. announced delayed annual 10-K filing

Rezolute Announces Publication of Rz402 Data in Diabetic Macular Edema (Dme) in Investigative Ophthalmology & Visual Science

マネジメント基準チェック /34